Brain TumorsNCT07620470
Spectral Precise Image Study for Brain Tumors
An observational study of Brain Tumors, run by Philips Clinical & Medical Affairs Global at 1 site in China.
Trial summary
The goal of this observational study is to explore the image quality of spectral CT deep learning reconstruction technology (Spectral Precise Image) of patients with confirmed brain tumors. The main question it aims to answer is: The Image Quality (IQ) and diagnostic confidence of Spectral Precise Image reconstructions Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Brain Tumors
- What is being tested?
- This is an observational data collection study
- Type of treatment
- Medical device
- How many people
- 120 participants
- Where
- 1 siteChina
- Study dates
- 28 Nov 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Who may be able to join
- Patients with clinical and radiology (MRI/CT) diagnosed brain tumors.
- Patients who underwent contrast enhanced scans using the Spectral CT 7500.
- Study participants with age ≥ 18 years old.
- Study participants that have signed Informed Consent Form (ICF)
Who cannot join
- The clinical data or radiological information is considered incomplete after evaluation by the investigator.
- Study participant that was enrolled in this study in the past
- Data from study participants deemed unsuitable for enrollment based on the investigator's evaluation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei
About this study
Official title: Clinical Study for Exploring Image Quality the Spectral Precise Image in Patients With Diagnosed Intracranial Tumors
The goal of this observational study is to explore the image quality of spectral CT deep learning reconstruction technology (Spectral Precise Image) of patients with confirmed brain tumors.
The main question it aims to answer is:
The Image Quality (IQ) and diagnostic confidence of Spectral Precise Image reconstructions
- Conditions
- Brain Tumors
- Being tested
- This is an observational data collection study
- Medical subject headings
- Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
This is an observational data collection studyDevice
This is an observational data collection study
What is being measured
The primary outcome is the main question the study is designed to answer.
Subjective Image quality using Likert score (1-5)
Image quality will be assessed by 2 radiologists using Likert score on a scale ranging from 1(poor) to 5(Excellent)
Measured: From date of image reconstruction until the date of image reading completion, anticipated 3Months.
Objective Image Quality
The objective quality of the image is evaluated by measuring the CT value shown in the image.
Measured: From date of image reconstruction until the date of image reading completion, anticipated 3Months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2026
- Study start28 Nov 2025
- Primary completion30 Aug 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain TumorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Other
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Philips Clinical & Medical Affairs Global
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Responsible party
- Sponsor
- Investigators
- Jing Wang, Principal investigator, 1277 Jiefang Avenue, Wuhan, Hubei Province, P. R. China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07620470
- Sponsor's protocol ID
- 301168
- Status last verified
- Nov 2025
- First submitted
- 24 Nov 2025
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study for Exploring Image Quality the Spectral Precise Image in Patients With Diagnosed Intracranial Tumors
- ClinicalTrials.gov ID
- NCT07620470
- Acronym / sponsor ID
- 301168
- Conditions
- Brain Tumors
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Philips Clinical & Medical Affairs GlobalIndustry (pharma, biotech, devices)
- Collaborators
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Study start
- 28 Nov 2025 (actual)
- Primary completion
- 30 Aug 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 2 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to explore the image quality of spectral CT deep learning reconstruction technology (Spectral Precise Image) of patients with confirmed brain tumors.
The main question it aims to answer is:
The Image Quality (IQ) and diagnostic confidence of Spectral Precise Image reconstructions
Study design
- Observational model
- Case only
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Key inclusion criteria (4 listed)
- Patients with clinical and radiology (MRI/CT) diagnosed brain tumors.
- Patients who underwent contrast enhanced scans using the Spectral CT 7500.
- Study participants with age ≥ 18 years old.
- Study participants that have signed Informed Consent Form (ICF)
Key exclusion criteria (3 listed)
- The clinical data or radiological information is considered incomplete after evaluation by the investigator.
- Study participant that was enrolled in this study in the past
- Data from study participants deemed unsuitable for enrollment based on the investigator's evaluation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| This is an observational data collection studyThis is an observational data collection study | Device | – |
Primary outcome
Subjective Image quality using Likert score (1-5)
Time frame: From date of image reconstruction until the date of image reading completion, anticipated 3Months.
Image quality will be assessed by 2 radiologists using Likert score on a scale ranging from 1(poor) to 5(Excellent)
Objective Image Quality
Time frame: From date of image reconstruction until the date of image reading completion, anticipated 3Months.
The objective quality of the image is evaluated by measuring the CT value shown in the image.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Brain Tumors
RecruitingObservational study
Tumor Related Epilepsy
Epilepsy, Cancer
Active, not recruitingPhase 1/2
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Glioblastoma, Gliosarcoma
Not yet recruitingObservational study
Clinical Outcomes of Stroke in MalIgnanCy
Stroke, Malignancies Multiple
Not yet recruitingObservational study
Twenty-five Years of Advanced RadioTherapy at San Raffaele Hospital
Malignant Tumor, Benign Neoplasm
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jing Wang principal investigator
1277 Jiefang Avenue, Wuhan, Hubei Province, P. R. China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain Tumors, run by Philips Clinical & Medical Affairs Global at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jing Wang (+8613986085216, xhwangjing@hust.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Subjective Image quality using Likert score (1-5) (time frame: From date of image reconstruction until the date of image reading completion, anticipated 3Months.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.